Nikkei 225
Kyowa Hakko Kirin
Kyowa Kirin is a Kirin-affiliated Japanese drugmaker strong in antibody therapeutics. Nikkei 225 constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
4151.T Updated Jul 11, 2026 2 AI consumers· 2 recurring
Annual return · 2026-07-10'21-6.7%'22+2.9%'23-17.4%'24+1.7%'25+10.7%YTD+6.9%
Money in ▸·
Kyowa Hakko Kirin~¥440B
▸ Money out·
Financials & Segments
- Total revenue · ~¥440B (FY2024)
- Segments · Nephrology · Oncology · Immunology and allergy
Revenue from
No refined links yet.
Pays to
No refined links yet.